Search

Your search keyword '"Carme Subirà"' showing total 3 results
Start Over Author "Carme Subirà" Publisher public library of science (plos)
3 results on '"Carme Subirà"'

2. Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients.

Author

Daniel Camprubí, Alex Almuedo-Riera, Helena Martí-Soler, Alex Soriano, Juan Carlos Hurtado, Carme Subirà, Berta Grau-Pujol, Alejandro Krolewiecki, and Jose Muñoz

Subjects
Medicine, Science
Abstract

Ivermectin has recently shown efficacy against SARS-CoV-2 in-vitro. We retrospectively reviewed severe COVID-19 patients receiving standard doses of ivermectin and we compared clinical and microbiological outcomes with a similar group of patients not receiving ivermectin. No differences were found between groups. We recommend the evaluation of high-doses of ivermectin in randomized trials against SARS-CoV-2.

Published
2020
Full Text
View/download PDF

3. Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients

Author

Carme Subirà, Berta Grau-Pujol, Alex Soriano, Daniel Camprubí, Juan Carlos Hurtado, Jose Muñoz, Alex Almuedo-Riera, Helena Martí-Soler, and Alejandro J. Krolewiecki

Subjects
Male, 0301 basic medicine, RNA viruses, Viral Diseases, Coronaviruses, animal diseases, Treatment outcome, Artificial Gene Amplification and Extension, Polymerase Chain Reaction, law.invention, 0302 clinical medicine, Ivermectin, Medical Conditions, Randomized controlled trial, law, Nasopharynx, Medicine and Health Sciences, Medicine, Public and Occupational Health, Pathology and laboratory medicine, Virus Testing, Multidisciplinary, Pharmaceutics, Organic Compounds, Middle Aged, Medical microbiology, Vaccination and Immunization, Hospitals, Intensive Care Units, Chemistry, Treatment Outcome, Infectious Diseases, Viruses, Physical Sciences, Female, Steroids, SARS CoV 2, Pathogens, Coronavirus Infections, Immunosuppressive Agents, medicine.drug, Research Article, Adult, medicine.medical_specialty, Farmacologia, Coronavirus disease 2019 (COVID-19), SARS coronavirus, Science, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Pneumonia, Viral, 030231 tropical medicine, Immunology, Antibodies, Monoclonal, Humanized, Research and Analysis Methods, Microbiology, Betacoronavirus, 03 medical and health sciences, Pharmacotherapy, Drug Therapy, Antiviral Therapy, Diagnostic Medicine, Internal medicine, parasitic diseases, Lack of efficacy, Humans, Molecular Biology Techniques, Pandemics, Molecular Biology, Retrospective Studies, Pharmacology, Biology and life sciences, SARS-CoV-2, business.industry, Organic Chemistry, Organisms, Viral pathogens, Chemical Compounds, COVID-19, Retrospective cohort study, Covid 19, COVID-19 Drug Treatment, Microbial pathogens, body regions, Health Care, 030104 developmental biology, Health Care Facilities, Preventive Medicine, business
Abstract

Ivermectin has recently shown efficacy against SARS-CoV-2 in-vitro. We retrospectively reviewed severe COVID-19 patients receiving standard doses of ivermectin and we compared clinical and microbiological outcomes with a similar group of patients not receiving ivermectin. No differences were found between groups. We recommend the evaluation of high-doses of ivermectin in randomized trials against SARS-CoV-2.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results